Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines
October 2021

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases
January 2022

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases
December 2021

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Infectious Diseases (Non HPV-Associated)

Title	Disease Target	Product
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals Molecular Therapy — March 2015	HIV	PENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo PLoS ONE — December 2013	HIV	PENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine Vaccine — September 2011	HIV	PENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers The Journal of Infectious Diseases — March 2019	Ebola	INO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines The Journal of Infectious Diseases — October 2018	Ebola	INO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus Microbes and Infection — December 2018	Zika	INO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization The Journal of Infectious Diseases — July 2018	Zika	INO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes Nature Communications — June 2017	Zika	INO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine npj Vaccines — November 2016	Zika	INO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates Science Translational Medicine — August 2015	MERS	INO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine Vaccine — May 2018	Influenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model Nature Communications — September 2017	Pseudomonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus The Journal of Infectious Diseases — March 2016	Chikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy Scientific Reports — July 2015	Dengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses Journal of Hepatology — February 2020	Hepatitis C	GLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial The Lancet Infectious Diseases — July 2019	MERS	INO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report The New England Journal of Medicine — October 2017	Zika	INO-4600

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases